AUTHORS
Parul Rai, MD, Victoria Okhomina2, Rima Zahr, DO, MS3, Guolian Other Person Kang, PhD4, Kenneth I Ataga, MD5
AFFILIATIONS
1 St Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St Jude Children's Research Hospital, Memphis, Tennessee, United States
3 University of Tennessee Health Sciences, Memphis, Tennessee, United States
4 St Jude Children's Research Hospital, Memphis, Tennessee, United States
5 University of Tennessee Health Sciences, Memphis, Tennessee, United States
ABSTRACT
Introduction
Kidney disease in sickle cell disease (SCD) manifests early in life and progresses with age. Glomerular hyperfiltration (HF) develops at a young age and precedes the development of persistent albuminuria (PA) and chronic kidney disease as patients age (Ataga et al., AJH 2026). Hydroxyurea (HU), the standard SCD-disease-modifying therapy, has shown some benefit in preserving organ function (Khargekar et al., Syst Rev 2024). The objective of this study was to evaluate the effect of HU on HF and PA in children and young adults with SCD.
Methods
We interrogated the database of the Sickle Cell Clinical Research and Intervention Program (SCCRIP; NCT 02098863), a lifespan SCD cohort study, and identified individuals aged 2-21 years with SCD genotype SS or Sβ0 thalassemia. Estimated glomerular filtration rate (eGFR) was estimated using the Schwartz equation in individuals <18 years and the creatinine-derived CKD-EPI-2021 equation in those ≥18 years. HF was defined as the median of the last 3 estimated GFR >135 mL/min, and PA was defined as urinary albumin-creatinine ratio (UACR) ≥30 mg/g in at least 2 of 3 consecutive measurements or a single UACR ≥100 mg/g if preceded by a normal UACR (UACR <30mg/g).
We evaluated the cross-sectional association of HU use with UACR and eGFR (median for PA and HF, (defined above). We also conducted linear and logistic regression analyses to examine this association after adjusting for age and sex. Because the continuous forms of UACR and eGFR exhibited non-normal residuals and heteroscedasticity, a Box-Cox transformation (λ = -0.31) on UACR and a natural log transformation on eGFR were applied prior to linear regression.
Results
In our study cohort of 241 participants (49.8% female; median age 17.7 years [IQR: 12.6, 20.6]), 88% used HU as a disease-modifying therapy for at least 1 year before their last UACR measurement. The prevalence of PA in this cohort was 42% (n=101). Compared with those without PA, a higher proportion of participants with PA had HF (q=0.03), as well as higher white blood cell counts and hemolysis markers (including lower hemoglobin levels and higher absolute reticulocyte counts). No significant differences in sex, HU use, age at HU initiation, or fetal hemoglobin (HbF) level (all q>0.05) were seen cross-sectionally between the PA and non-PA groups. In the regression models, after adjusting for age and sex, HU use for at least 1 year was not significantly associated with UACR (β = 0.001, 95% CI: -0.01 to 0.01, p = 0.83) or presence of PA (OR=1.04, 95% CI: 0.88-1.23, p=0.61). Of the 241 participants in our study cohort, eGFR was calculated for 200 participants (50.5% female; median age=18.5 [IQR: 14.6, 21.1]) and HF was observed in 61.5% (n=123). Compared with those without HF, those with HF had higher hemolysis (lower hemoglobin and higher absolute reticulocyte count), lower HbF, and a higher proportion of participants with PA. No significant cross-sectional differences in sex, HU use, or age at HU initiation were observed between the HF and non-HF groups. In the regression models after adjusting for age and sex, a minimum of 1 year of HU use was not associated with GFR (β = 0.001, 95% CI: -0.0002 to 0.002, p = 0.1) or presence of HF (OR=0.94, 95% CI: 0.79 -1.13, p=0.47).
Conclusion
In our adolescent and young adult cohort, the likelihood of having PA or HF was not lowered with HU use. Consistent with previous studies, we found that the presence of PA or HF was associated with worse hemolysis, lower hemoglobin, higher WBC, and lower HbF, suggesting a contribution of hemolysis and inflammation to the pathophysiology of sickle nephropathy. While we observed no renal benefit with HU in this cross-sectional analysis, longitudinal analyses are needed to determine whether induction of high HbF with HU delays or prevents the development of kidney disease.
DISCLOSURES
Parul Rai, MD: No relevant conflicts of interest to declare.